Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies
Identifieur interne : 001862 ( Main/Exploration ); précédent : 001861; suivant : 001863Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies
Auteurs : A. Horváth [Hongrie] ; I. Andersen [Danemark] ; K. Junker [Danemark] ; B. Lyck Fogh-Schultz [Danemark] ; E. Holm Nielsen [Danemark] ; S. Gizurarson [Islande] ; O. Andersen [Danemark] ; J. Kármán [Hongrie] ; E. Rajnavölgyi [Hongrie] ; A. Erdei [Hongrie] ; S.-E Svehag [Danemark]Source :
- Antiviral Research [ 0166-3542 ] ; 2001.
English descriptors
- KwdEn :
- Teeft :
- 6irus, 6irus infection, Amyloid, Andersen, Anti6iral, Anti6iral research, Antiviral, Antiviral antibodies, Antiviral effect, Benzalkonium chloride, Binding studies, Blood samples, Body weight, Complex type, Control mice, Dependent binding, Different compounds, Elisa, Elisa results, Elsevier science, Further studies, Galactose, Hemagglutinin, Hemagglutinin molecules, Holm nielsen, Hor6ath, Human serum amyloid, Infection, Initial infection, Intranasal, Intranasal administration, Intranasally, Local irritation, Mannose, Methylcellulose, Mild infection, Modest inhibition, Mouse, Mucociliary clearance, Nacl, Nasal, Nasal cavity, Nasal mucosa, Nasal secretion, Normal appearance, Normal body weight, Oligosaccharide, Optical density, Other groups, Primary infection, Reassortant virus, Serum albumin, Serum amyloid, Silver staining, Softigen, Split virions, Subunit, Subunit vaccine, Terminal mannose, Total dose, Vaccine, Viral, Viral exposure, Viral infection, Virion, Virus, Virus hemagglutinin, Virus infection, Virus infections, Virus preincubated, Virus strain, Virus strains, Vivo studies, Western blot, Winsloewparken odense.
Abstract
Abstract: Serum amyloid P component (SAP) binds in vitro Ca2+-dependently to several ligands including oligosaccharides with terminal mannose and galactose. We have earlier reported that SAP binds to human influenza A virus strains, inhibiting hemagglutinin (HA) activity and virus infectivity in vitro. These studies were extended to comprise five mouse-adapted influenza A strains, two swine influenza A strains, a mink influenza A virus, a ferret influenza A reassortant virus, a influenza B virus and a parainfluenza 3 virus. The HA activity of all these viruses was inhibited by SAP. Western blotting showed that SAP bound to HA trimers, monomers and HA1 and HA2 subunits of influenza A virus. Binding studies indicated that galactose, mannose and fucose moieties contributed to the SAP reacting site(s). Intranasal administration of human SAP to mice induced no demonstrable toxic reactions, and circulating antibodies against SAP were not detected. Preincubation of virus (A/Japan/57) with SAP prevented primary infection of mice and development of antiviral antibodies. After a single intranasal administration of SAP (40 μg) 1 h before primary infection with virus (2LD50), nine out of 10 mice survived on day 10 and these mice approached normal body weight, whereas control mice (one out of five surviving on day 10) died. The data provide evidence of the potential of intranasally administered SAP for prophylactic treatment of influenza A virus infections in humans.
Url:
DOI: 10.1016/S0166-3542(01)00158-9
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000728
- to stream Istex, to step Curation: 000728
- to stream Istex, to step Checkpoint: 000689
- to stream Main, to step Merge: 001902
- to stream Main, to step Curation: 001862
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies</title><author><name sortKey="Horvath, A" sort="Horvath, A" uniqKey="Horvath A" first="A" last="Horváth">A. Horváth</name></author><author><name sortKey="Andersen, I" sort="Andersen, I" uniqKey="Andersen I" first="I" last="Andersen">I. Andersen</name></author><author><name sortKey="Junker, K" sort="Junker, K" uniqKey="Junker K" first="K" last="Junker">K. Junker</name></author><author><name sortKey="Lyck Fogh Schultz, B" sort="Lyck Fogh Schultz, B" uniqKey="Lyck Fogh Schultz B" first="B" last="Lyck Fogh-Schultz">B. Lyck Fogh-Schultz</name></author><author><name sortKey="Holm Nielsen, E" sort="Holm Nielsen, E" uniqKey="Holm Nielsen E" first="E" last="Holm Nielsen">E. Holm Nielsen</name></author><author><name sortKey="Gizurarson, S" sort="Gizurarson, S" uniqKey="Gizurarson S" first="S" last="Gizurarson">S. Gizurarson</name></author><author><name sortKey="Andersen, O" sort="Andersen, O" uniqKey="Andersen O" first="O" last="Andersen">O. Andersen</name></author><author><name sortKey="Karman, J" sort="Karman, J" uniqKey="Karman J" first="J" last="Kármán">J. Kármán</name></author><author><name sortKey="Rajnavolgyi, E" sort="Rajnavolgyi, E" uniqKey="Rajnavolgyi E" first="E" last="Rajnavölgyi">E. Rajnavölgyi</name></author><author><name sortKey="Erdei, A" sort="Erdei, A" uniqKey="Erdei A" first="A" last="Erdei">A. Erdei</name></author><author><name sortKey="Svehag, S E" sort="Svehag, S E" uniqKey="Svehag S" first="S.-E" last="Svehag">S.-E Svehag</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BC0097C8FF89A83535F26FDB080FEFAD7844630C</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0166-3542(01)00158-9</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-S85P8GQC-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000728</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000728</idno><idno type="wicri:Area/Istex/Curation">000728</idno><idno type="wicri:Area/Istex/Checkpoint">000689</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000689</idno><idno type="wicri:doubleKey">0166-3542:2001:Horvath A:serum:amyloid:p</idno><idno type="wicri:Area/Main/Merge">001902</idno><idno type="wicri:Area/Main/Curation">001862</idno><idno type="wicri:Area/Main/Exploration">001862</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies</title><author><name sortKey="Horvath, A" sort="Horvath, A" uniqKey="Horvath A" first="A" last="Horváth">A. Horváth</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Immunology, L.Eötvös University, Göd</wicri:regionArea><wicri:noRegion>Göd</wicri:noRegion></affiliation></author><author><name sortKey="Andersen, I" sort="Andersen, I" uniqKey="Andersen I" first="I" last="Andersen">I. Andersen</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Immunology and Microbiology, SDU-Odense University, Winsloewparken 21.1, DK-5000 Odense C</wicri:regionArea><wicri:noRegion>DK-5000 Odense C</wicri:noRegion></affiliation></author><author><name sortKey="Junker, K" sort="Junker, K" uniqKey="Junker K" first="K" last="Junker">K. Junker</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Immunology and Microbiology, SDU-Odense University, Winsloewparken 21.1, DK-5000 Odense C</wicri:regionArea><wicri:noRegion>DK-5000 Odense C</wicri:noRegion></affiliation></author><author><name sortKey="Lyck Fogh Schultz, B" sort="Lyck Fogh Schultz, B" uniqKey="Lyck Fogh Schultz B" first="B" last="Lyck Fogh-Schultz">B. Lyck Fogh-Schultz</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Immunology and Microbiology, SDU-Odense University, Winsloewparken 21.1, DK-5000 Odense C</wicri:regionArea><wicri:noRegion>DK-5000 Odense C</wicri:noRegion></affiliation></author><author><name sortKey="Holm Nielsen, E" sort="Holm Nielsen, E" uniqKey="Holm Nielsen E" first="E" last="Holm Nielsen">E. Holm Nielsen</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Anatomy and Neurobiology, SDU-Odense University, Winsloewparken 21.1, DK-5000 Odense C</wicri:regionArea><wicri:noRegion>DK-5000 Odense C</wicri:noRegion></affiliation></author><author><name sortKey="Gizurarson, S" sort="Gizurarson, S" uniqKey="Gizurarson S" first="S" last="Gizurarson">S. Gizurarson</name><affiliation wicri:level="1"><country xml:lang="fr">Islande</country><wicri:regionArea>Department of Pharmacy, Pharmacology and Toxicology, Iceland University, Reykjavik</wicri:regionArea><wicri:noRegion>Reykjavik</wicri:noRegion></affiliation></author><author><name sortKey="Andersen, O" sort="Andersen, O" uniqKey="Andersen O" first="O" last="Andersen">O. Andersen</name><affiliation wicri:level="3"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Medicine, Hvidovre Hospital, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Karman, J" sort="Karman, J" uniqKey="Karman J" first="J" last="Kármán">J. Kármán</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Immunology, L.Eötvös University, Göd</wicri:regionArea><wicri:noRegion>Göd</wicri:noRegion></affiliation></author><author><name sortKey="Rajnavolgyi, E" sort="Rajnavolgyi, E" uniqKey="Rajnavolgyi E" first="E" last="Rajnavölgyi">E. Rajnavölgyi</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Immunology, L.Eötvös University, Göd</wicri:regionArea><wicri:noRegion>Göd</wicri:noRegion></affiliation></author><author><name sortKey="Erdei, A" sort="Erdei, A" uniqKey="Erdei A" first="A" last="Erdei">A. Erdei</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Immunology, L.Eötvös University, Göd</wicri:regionArea><wicri:noRegion>Göd</wicri:noRegion></affiliation></author><author><name sortKey="Svehag, S E" sort="Svehag, S E" uniqKey="Svehag S" first="S.-E" last="Svehag">S.-E Svehag</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Department of Immunology and Microbiology, SDU-Odense University, Winsloewparken 21.1, DK-5000 Odense C</wicri:regionArea><wicri:noRegion>DK-5000 Odense C</wicri:noRegion></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Danemark</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Antiviral Research</title><title level="j" type="abbrev">AVR</title><idno type="ISSN">0166-3542</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">52</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="43">43</biblScope><biblScope unit="page" to="53">53</biblScope></imprint><idno type="ISSN">0166-3542</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral effect</term><term>Influenza A virus</term><term>Serum amyloid P component</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>6irus</term><term>6irus infection</term><term>Amyloid</term><term>Andersen</term><term>Anti6iral</term><term>Anti6iral research</term><term>Antiviral</term><term>Antiviral antibodies</term><term>Antiviral effect</term><term>Benzalkonium chloride</term><term>Binding studies</term><term>Blood samples</term><term>Body weight</term><term>Complex type</term><term>Control mice</term><term>Dependent binding</term><term>Different compounds</term><term>Elisa</term><term>Elisa results</term><term>Elsevier science</term><term>Further studies</term><term>Galactose</term><term>Hemagglutinin</term><term>Hemagglutinin molecules</term><term>Holm nielsen</term><term>Hor6ath</term><term>Human serum amyloid</term><term>Infection</term><term>Initial infection</term><term>Intranasal</term><term>Intranasal administration</term><term>Intranasally</term><term>Local irritation</term><term>Mannose</term><term>Methylcellulose</term><term>Mild infection</term><term>Modest inhibition</term><term>Mouse</term><term>Mucociliary clearance</term><term>Nacl</term><term>Nasal</term><term>Nasal cavity</term><term>Nasal mucosa</term><term>Nasal secretion</term><term>Normal appearance</term><term>Normal body weight</term><term>Oligosaccharide</term><term>Optical density</term><term>Other groups</term><term>Primary infection</term><term>Reassortant virus</term><term>Serum albumin</term><term>Serum amyloid</term><term>Silver staining</term><term>Softigen</term><term>Split virions</term><term>Subunit</term><term>Subunit vaccine</term><term>Terminal mannose</term><term>Total dose</term><term>Vaccine</term><term>Viral</term><term>Viral exposure</term><term>Viral infection</term><term>Virion</term><term>Virus</term><term>Virus hemagglutinin</term><term>Virus infection</term><term>Virus infections</term><term>Virus preincubated</term><term>Virus strain</term><term>Virus strains</term><term>Vivo studies</term><term>Western blot</term><term>Winsloewparken odense</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Serum amyloid P component (SAP) binds in vitro Ca2+-dependently to several ligands including oligosaccharides with terminal mannose and galactose. We have earlier reported that SAP binds to human influenza A virus strains, inhibiting hemagglutinin (HA) activity and virus infectivity in vitro. These studies were extended to comprise five mouse-adapted influenza A strains, two swine influenza A strains, a mink influenza A virus, a ferret influenza A reassortant virus, a influenza B virus and a parainfluenza 3 virus. The HA activity of all these viruses was inhibited by SAP. Western blotting showed that SAP bound to HA trimers, monomers and HA1 and HA2 subunits of influenza A virus. Binding studies indicated that galactose, mannose and fucose moieties contributed to the SAP reacting site(s). Intranasal administration of human SAP to mice induced no demonstrable toxic reactions, and circulating antibodies against SAP were not detected. Preincubation of virus (A/Japan/57) with SAP prevented primary infection of mice and development of antiviral antibodies. After a single intranasal administration of SAP (40 μg) 1 h before primary infection with virus (2LD50), nine out of 10 mice survived on day 10 and these mice approached normal body weight, whereas control mice (one out of five surviving on day 10) died. The data provide evidence of the potential of intranasally administered SAP for prophylactic treatment of influenza A virus infections in humans.</div></front></TEI><affiliations><list><country><li>Danemark</li><li>Hongrie</li><li>Islande</li></country><region><li>Hovedstaden</li></region><settlement><li>Copenhague</li></settlement></list><tree><country name="Hongrie"><noRegion><name sortKey="Horvath, A" sort="Horvath, A" uniqKey="Horvath A" first="A" last="Horváth">A. Horváth</name></noRegion><name sortKey="Erdei, A" sort="Erdei, A" uniqKey="Erdei A" first="A" last="Erdei">A. Erdei</name><name sortKey="Karman, J" sort="Karman, J" uniqKey="Karman J" first="J" last="Kármán">J. Kármán</name><name sortKey="Rajnavolgyi, E" sort="Rajnavolgyi, E" uniqKey="Rajnavolgyi E" first="E" last="Rajnavölgyi">E. Rajnavölgyi</name></country><country name="Danemark"><noRegion><name sortKey="Andersen, I" sort="Andersen, I" uniqKey="Andersen I" first="I" last="Andersen">I. Andersen</name></noRegion><name sortKey="Andersen, O" sort="Andersen, O" uniqKey="Andersen O" first="O" last="Andersen">O. Andersen</name><name sortKey="Holm Nielsen, E" sort="Holm Nielsen, E" uniqKey="Holm Nielsen E" first="E" last="Holm Nielsen">E. Holm Nielsen</name><name sortKey="Junker, K" sort="Junker, K" uniqKey="Junker K" first="K" last="Junker">K. Junker</name><name sortKey="Lyck Fogh Schultz, B" sort="Lyck Fogh Schultz, B" uniqKey="Lyck Fogh Schultz B" first="B" last="Lyck Fogh-Schultz">B. Lyck Fogh-Schultz</name><name sortKey="Svehag, S E" sort="Svehag, S E" uniqKey="Svehag S" first="S.-E" last="Svehag">S.-E Svehag</name><name sortKey="Svehag, S E" sort="Svehag, S E" uniqKey="Svehag S" first="S.-E" last="Svehag">S.-E Svehag</name></country><country name="Islande"><noRegion><name sortKey="Gizurarson, S" sort="Gizurarson, S" uniqKey="Gizurarson S" first="S" last="Gizurarson">S. Gizurarson</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001862 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001862 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BC0097C8FF89A83535F26FDB080FEFAD7844630C
|texte= Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies
}}
| This area was generated with Dilib version V0.6.33. |  |